Morning. Hi, I'm Dr. Michael Perry. I have with me Michael Holder, our CFO. I'm CEO of AVITA Medical, and would like to take you through an abridged version of our corporate presentation, and then we'll open it up for Q&A. Thanks for joining. This slide is a legal disclaimer, as we're traded both in the U.S. on the Nasdaq and here in Australia on the ASX. If you direct your attention to the right-hand side of this slide, what you see is a human figure. Sorry, to the left-hand side. You see a human figure with a yellow ball, which is meant to be a patch of healthy skin or a small biopsy that's taken from the patient. Going counterclockwise, you see the RECELL device. The black well is a well where we put a proprietary enzyme and the tissue is soaked in there for about 10 minutes. The white well is loaded with buffer, not heated, whereas the black well is heated. The final well on the right-hand side of the device, showing up, I believe in green or in yellow, depending upon your computer setting. That is a 1-micron filter, just to filter out any hair follicles or larger pieces of skin that aren't fully disaggregated cells, so they don't clog up our spray nozzle that we provide. Within 25-30 minutes at point of care from taking that initial biopsy, going through the system, you've got spray-on skin cells. We're currently approved for burns in the United States. We also have TGA approval as well as EU CE mark and other approvals around the world. Currently, we're marketing only in the U.S. Turning your attention to the right-hand side of the slide, here we're showing really that this is a platform technology. We have trials ongoing in vitiligo, in trauma, burns and scalds were already approved. Chronic wounds, we have pilot data that are very strong. Scar revision, some pilot data, on and on. This is not a comprehensive list. There's a lot more that goes with the RECELL system. Looking at value creation over the last little while, if we look at our key accomplishments on the left-hand side of this slide, you can see that the quarter ending December 31, 2021, had revenue growth of 35% versus the same quarter in 2020. We did get FDA approval of our ease-of-use device, and I'll be talking a little bit more about that coming up. Our partner in Japan, COSMOTEC, gained PMDA, that's the Japanese health authority, approval of burns in Japan. I'll be talking a little bit about that additionally. Both our vitiligo pivotal trial, this is a registration trial, as well as our soft tissue pivotal trial, have completed enrollment of their patients. Now they're following the patients. I'll speak a little bit about those trials and when we anticipate submitting PMAs, top-line data release, as well as we anticipate our approval of these two indications. We did get a transitional pass-through payment for the outpatient setting. This is indication agnostic, so it will work, that outpatient code that was provided by CMS will basically cover any indication. It'll cover burns, it'll cover soft tissue. We're in a good position there. The c is something that's not easy to gain, and we're proud to have it. It is CMS only, so it starts out covering about 15% of patients' lives, insofar as the patient population that might be eligible for outpatient reimbursement. We work with the commercial payers. Once you've got the TPT, it really provides an anchor for moving forward with the commercials. In both epidermolysis bullosa and rejuvenation, one being a genetic disease of the skin, EB, where the top layer of skin, the epidermis, is not appropriately anchored to the underlying dermis. That's due to a single gene defect. It is specifically collagen VII A1 that normally binds the epidermis to the dermis. We've established proof of concept there. In rejuvenation, we've also have initial proof of concept on the delivery of reverse aged skin cells. I'll be talking a little bit more about that and showing you some histology relative to how the skin is forming after it's been genetically manipulated. Two milestones ahead, we have top-line results for vitiligo as well as vitiligo submission in the second half of this calendar year and vitiligo commercial launch in the second half of next year. Similarly for the soft tissue or trauma indication, we are looking at similar timelines, top-line data and PMA submission in the second half of this calendar year, approval in the second half of 2023. This is actually for soft tissue, bringing in of our timeline by approximately nine months, so ahead of schedule and now right neck and neck with vitiligo. We're pleased we had a very nice enrollment curve when COVID started to let up. Regarding the outpatient launch, I did mention we have the transitional pass-through payment, but another element that is, I would say valuable, for the launch in outpatient and in general, is our new ease-of-use device that we are starting to launch now. We're starting it, of course, in our established accounts because we'll ultimately be utilizing this device for all indications, let's just say. I'll talk a little bit more about its attributes and why it's an ease-of-use device in an upcoming slide. In the second half of this calendar year, we'll also be looking with the FDA at both the reverse aging product and the epidermolysis bullosa genetic correction, and seeing what, if any, additional preclinical studies would be required before we submit an IND, Investigational New Drug application, and go into first in patients. Relative to our Japan approval, the next step is for our partner there, COSMOTEC, to be speaking with the MHLW, Ministry of Health, Labor and Welfare, now that they have PMDA approval, and the MHLW will be working with them to establish a price for reimbursement. Moving on to our development pipeline. Here, you can see the various indications down the left and, on the top, you can see where the product is in its development cycle. For acute thermal burns, we are approved, and we've been selling for a couple of years. We did start sales in January of 2019, and of course, COVID hit us in 2020, but we've continued to grow. Japanese approval by the PMDA, we just received, so I've mentioned that. Both the vitiligo and soft tissue trials are ongoing and have completed their enrollment. As I mentioned, in epidermolysis bullosa and in rejuvenation, we established proof of concept, so we're moving out of discovery into feasibility. Insofar as innovation on the device platform, we have the new ease-of-use device, which is recently approved by the FDA. We are working on design features for the fully automated device, which we believe will be very important to enable the vitiligo indication. That's going to be a different call point. It'll be in the office of interventional dermatologists and plastic surgeon. For a small company, we're doing a lot, and this should be creating a lot of value over the next 18-24 months. Here, we see the opportunity for the pipeline. Looking on the left-hand side of the slide, you see approximately $6.8 billion of opportunity. This is highly de-risked. We're already approved in the U.S. in burns. We have the soft tissue indication coming up, and that, when approved in the second half of 2023 that we're predicting, that's almost twice the size of the burns indication; it's a $1 billion addressable market. If we look at vitiligo in the blue, we see that that's multiple of the soft tissue, $5.2 billion addressable market, total addressable market in the U.S. These are just for the U.S. Those add up to $6.8 billion and are highly de-risked because we've already utilized the RECELL device in a lot of patients. I'll speak to that, the number of publications we have already, as well as the number of patients who have been treated. Very low risk. Higher risk, but not, you know, extraordinarily high, regular risk, and not de-risked is our cell-based gene therapy programs. Rejuvenation that I just mentioned, where we're reverse aging the skin biologically using RNA telomerase. That's a $15 billion market in the U.S. alone. Epidermolysis bullosa, which is just one of approximately 50 genodermatoses or genetic diseases of the skin, and just that's one indication. Right now, there are no treatments available other than symptomatic treatment, support dressing. I'll be talking about that a little bit, but that would be an $800 million opportunity in the U.S. alone, combined over $22 billion of total market opportunity here. As I mentioned, the part on the left-hand side of the prior slide is highly de-risked. Here you see acute wounds, including burns. You see vitiligo and chronic wounds which we're currently not progressing, because we can't do everything at the same time, and we don't want to burn through all of our cash quickly. But you can see the number of patients as well as the number of presentations and publications in each of these indications. So very highly de-risked. The product has been, you know, has already shown efficacy in these indications, has been used many times. Overall, when we look at since the company was launched, since the days of Fiona Wood in 2002, over 15,000 patients have been treated utilizing the RECELL device. Talking a little bit about that C code for the outpatient sector, that became effective January 1st of this calendar year. The code is C1832, and you can read the indication there. It basically reimburses for the cost of the device, our ASP. The code is generally utilized for two to three years and then converted to a permanent code. Again, Medicare covers approximately 15% of patients' lives. We'll be working with the commercial payers to enable a very broad reimbursement for the outpatient opportunity. Again, it's indication agnostic, so applies equally to burns and soft tissue wounds. Here, as I mentioned, the new ease of use device. It has a reduced number of steps that the number of steps required from taking the biopsy to having the spray on skin cells has been reduced by 30%. The process is easier insofar as it does not require a second pair of hands outside the sterile field. Previously, the packaging had it so that there had to be a nurse or another attendant outside of the sterile field opening variety of packages for scalpels, for syringes, for various elements of the RECELL system. Now it's basically you take the plastic box that has all of the components sterilized in it, take it out of the cardboard box, put it into the sterile field, and you're ready to go. There's no passing of continuous elements of the system. Improved usability. Of the physicians that we surveyed, 94% of the users said they believe it'll reduce their workload and allow them additional time to perform other surgeries or other duties that they have. We're very excited about this next generation of machine. We have a further one that's in development, completely automated, that's going to be used in the dermatologist office. That's in design phase and now moving into development. Here we see the vitiligo study enrollment. You can see the step-up that happened in 2021 and last year really. Enrollment is complete now, as I mentioned on that second slide beforehand. We anticipate FDA submission of a PMA in the second half of this calendar year. Here on the right-hand side, we just have a picture from a prior study, where you can see a negative control, and you can see a RECELL treated patch, and there's a full return of pigmentation there. This is meant for stable vitiligo. Vitiligo is an autoimmune disease, where the patient's own immune system attacks its melanocytes, and they stop producing the pigment. This, you know, compared to, for example, excimer laser, that recently received reimbursement from Cigna, that was at a rate of $30,000 approximately per year, the reimbursement for the laser. That's a continuous therapy that's required, and it requires, you know, like twice a week to be in the dermatologist office, whereas this is a one and done. As far as we know, it is durable. Early completion of our soft tissue reconstruction or trauma trial. Here you can see COVID impact, you know, was one or two patients, maybe, you know, six, but, you know, low to mid single digits. As we started to emerge from COVID in the second half of last calendar year, 2021, we were able to enroll all of the patients ahead of schedule. Again, FDA submission of a PMA for this indication is expected in the second half of this calendar year with approval in the second half of next calendar year. On the right-hand side, you can see a patient. This is actually necrotizing fasciitis. The patient very, very deeply needed to be dissected. By the way, necrotizing fasciitis, for those of you who are not aware of that's basically the flesh-eating bacteria. The patient had to have the skin deeply resected from the axillary area, the armpit, all the way to the hip. One-year post-treatment, although it may not look great to you, and I don't have a control, but this is a wonderful outcome compared to current standard of care. Just showing what RECELL can do in soft tissue reconstruction. By and large, though, the wounds in soft tissue are small, unlike burns that come in, you know, very large sizes, high total body surface area. Generally, the preponderance of soft tissue wounds are small. Small meaning they would only require one RECELL kit. Little bit more about it relative to the commercial launch of the soft tissue indication. Currently, there are 136 or so burn centers in the United States. They're our current target where we are currently selling the RECELL system. About 50% of these burn centers are co-located with level one, level two trauma centers. There's a good number of our physicians who have already been trained, who will be utilizing the RECELL system and are already trained on it from the burns. Some a few are actually utilizing it off-label. We can't promote it, of course, for soft tissue until we have the indication. That said, we're going to go to an additional 230 high-volume trauma centers once we get the approval. When reimbursement is in place, the CPT codes will be the same, the outpatient C code will be the same. It's the same treatment protocol, stabilize the patient, debride the wound, clean the wound, and then is the patient you know requiring a skin graft? If so, let's use RECELL. It's the same unmet medical need as burns, relative to reduction of donor area. You know, the likelihood of this trial coming out positive is very high, and it's a very large opportunity, and it really leverages our current infrastructure, our commercial and sales infrastructure, relative to burns. Talking a little bit about our cell and gene therapy programs, if you look on the left-hand side of this slide, that's the patient, that figure that I started out with when I described the basic use of the RECELL system to repair defects such as burns, or soft tissue wounds. Our future platform on the right-hand side of the slide, you can see the only real difference is in this greenish colored box, where after disaggregation and before spraying on, these skin cells are genetically modified, either genetically corrected for EB, single mutation on collagen VII A1 or adding RNA telomerase. We're doing the EB program, epidermolysis bullosa, with the Gates Center for Regenerative Medicine at the University of Colorado in Denver, and we're working on the rejuvenation program with the Houston Methodist Research Institute. We have a right to acquire the intellectual property globally for these two indications, should they pan out to be effective. Next steps for the cell and gene therapies, we've established proof of concept for both in an immunocompromised rodent model. Next we'll be, you know, looking at that, perfecting those data, and then interacting with the FDA to see which IND-enabling studies, investigational new drug application is what IND stands for, which preclinical studies, which additional animal studies might be required before we go into first in human. As I said, now we're optimizing, and then we're going to be meeting with the FDA. Here, you see, the epidermolysis bullosa, that single gene mutation, well, which is a very serious disease, albeit an orphan disease, in its worst form, recessive dystrophic epidermolysis bullosa or RDEB. What we're showing here in the left-hand side of the slide in the figure is keratinocytes and fibroblasts. These can be corrected by gene editing technologies that are currently available, put into an immunocompromised mouse. We show that we can grow normal skin, and then on a histology, we can see that the epidermal layer is bound appropriately to the dermal layer. This is with utilizing the spray on system as opposed to growing sheets of corrected cells, which a couple of other companies are doing. The sheets are very difficult to maneuver with, and also, the sheets of corrected cells end up being a patchwork because they need to be individually stapled or sutured onto the patient, whereas the spray will adhere to areas that do not have epidermis. Here you can see not a recessive dystrophic, but a heterogeneous form of epidermolysis bullosa. Skin fragility is the real issue when these individuals are even just putting on clothing, their epidermis will just slough off. Here you can see multiple scarring in between the raw areas. The cost burden for these patients just to manage them, not to correct their disease, is about $200,000-$500,000 a year. What we're offering is the opportunity for a curative, efficient, and convenient suspension opportunity with genetically corrected cells where we've proven the concept so far. So far as the reverse aging, again, we've utilized the RECELL system to disaggregate the cells. At the point of care, we can introduce mRNA telomerase or hTERT, that's human telomerase reverse transcriptase. That not only lengthens the telomere but it also provides nuclear changes where the skin cells are acting as though they're very young skin cells, five, six years of age. If you look at the bottom right in the black little square, what you see there is immunohistochemistry, and those pink dots along the top of the surface there of the skin, it's showing production of collagen and elastin, which aged cells, people say over 50, certainly over 55 years of age, those cells are not gonna be producing collagen and elastin. If any, you know, at a small rate. We're quite hopeful for this as a rejuvenation indication. Although initially, we'll probably follow the route of Botox, where they went for a real indication, i.e., there was a risk-benefit, as opposed to rejuvenation, where there's really no risk. You know, the risk is getting wrinkles and some age spots. Talking a little bit about corporate financial overview. You can see year-over-year, since we gained approval in September of 2018, 2019, 2021, you can see how our commercial sales have ramped. We've provided guidance for calendar year 2022 of $30 million. We're still seeing some pressure due to the nurse shortage. We're having to do a lot of trainings. Last quarter we did about 600 trainings. Seems to be, but you can see there, and we exited the year with over $100 million in cash, and we have no debt on our balance sheet. Of course, our share price is depressed along with the entire sector, which has gone down substantially in the last month or two. We do have a strong patent estate that protects our technology and in addition to the PMA, where in order for somebody to come in, they would actually have to run the clinical trials and show that they are having an equal effect as we have. And not violating any of our patents in so doing. So 18 granted and 24 and more coming. For example, our fully automated system, as well as our ease-of-use system. New patents have been filed and if issued, and it looks good right now, those will give us 20-year new life on those patents. Here you see our leadership team, myself and Michael on the left and the rest. Happy to say that we have a very solid, very experienced leadership team who are really performing well, given the challenges that we have had, and we're looking forward to having more time face-to-face, now that COVID is abating. Risk factors and disclosures, again, as we're publicly traded. Important safety information as we're selling the product in burns currently in the United States as well as in parts of Australia, and basically a revolutionary treatment there. It's been over 50 years since the skin grafting procedure has been changed and 20 years in the United States since a new PMA, as opposed to a 510(k), which is basically a copy of a current technology. A PMA, an original randomized controlled clinical trial showing outcomes that are superior versus the current standard of care, a split-thickness autograft. I'll stop on this slide, which recapitulates our key accomplishments and key milestones moving forward, and I'd like to open it for Q&A. Mike, we received a number of questions prior to the call, and I'm going through those. A number of them are sort of repetitive on similar topics, and some of them have been addressed by your presentation. First question, congratulations on the new agreement with Premier. Can you provide a little color on what this agreement might mean for revenues in 2022 and otherwise thereafter? And does this agreement help you with burns or soft tissue reconstruction more so? Thank you for the question. The Premier agreement is, you know, Premier is one of the largest GPOs in the U.S., and for them to actually have it accepted in their network of hospitals really gives us an in to for both burns, although they cover only a few burn centers, they do cover a lot of trauma centers. I think we'll see the real impact going forward in soft tissue. Michael, is there anything you would like to add to that? No, I think you covered it really well. You know, just to reiterate, we don't expect a whole lot in 2022, largely because of the burns focus. In 2023 and thereafter and beyond, it should begin to make a material difference. Thank you. Next question has to do with the recent announcement relative to BARDA support of the soft tissue reconstruction trial and you know, how much support, financial support, what is the dollar support of BARDA in this agreement. And is there any potential benefit beyond just the soft tissue-based clinical trial. The current clinical trial is fully enrolled, and is awaiting the period of follow-up time, and then top line data will be released, as I mentioned. The BARDA funding, I guess it's important to note that, where this came from, and BARDA's remit for the burns division has actually been broadened. They are responsible for both burns as well as acute traumatic wounds, whether that's, you know, falling off a motorcycle, but more likely in their case it's shrapnel and, you know, those types of acute wound injuries in a mass casualty situation. BARDA is going to be helping us. They're not retrospectively going back and funding the trial. Moving forward, for example, if we decide after PMA review but prior to PMA approval, during those nine or 10 months, that we wanna go forward, for example, with compassionate use or a continued access program, and generally to, you know, drive awareness, and utilization in this indication. That's where BARDA is supporting us. I don't believe that we've released publicly a dollar amount, so, I unfortunately can't speak to that right now. That's right. We haven't actually received approval from BARDA to announce the funding, so we're actually not allowed to. There are a number of questions around operating expenses, cash burn rate. When will you guys reach profitability? Sort of what is the thought process and strategy with your current pathway and plans for those expenditures? Yeah. Let me start, Michael, and then I'll pass it back to you to go into some details on the OpEx and our cash burn. Relative to profitability, we've got, you know, approximately 50% of our shareholders in Australia here and 50% of our shareholders in the U.S., on the Nasdaq. There's a fundamental difference between the two. Usually, the Australian market is looking for how quickly can a company move into an indication, establish sales in that indication and cross over EBITDA, break even and go into real profitability. I would say, you know, back of the envelope kind of calculation, we're already there in burns, I would imagine. We can't actually do that calculation and assign operating expenses, et cetera. Otherwise, that's in the U.S. called segment reporting. We'd have to separately, as we go forward as a company, continuously report on our total revenue, but on how did we do in soft tissue this quarter? How did we do in vitiligo, you know, the following quarter, whatever. Basically that's in perpetuity. There's no way to back out of it. The fundamental difference being in the United States, what investors are looking for is top line growth as quickly as possible. It's getting new indications, getting that, you know, first hockey stick, in, for example, for our soft tissue and for vitiligo indications which are coming up next year for approval. You know, that's what that market wants. We're moving forward aggressively and of course, at an 80%+ profit margin. We are going to hit profitability in a reasonable timeframe. When we do, we will be a very robust company because we will have all these various indications. Michael, a little bit more on OpEx, cash burn, et cetera. Yes, I can. I just want to confirm that on a direct cost basis, our burns business has become actually quite profitable. Just to follow up on that point, Mike. Yeah. As we look at our operating expenses over the next couple of years, basically we're investing, if you will, around $7 million per quarter on average $7 million-$8 million. It's truly largely an investment. The big drivers there are our clinical trials in vitiligo and soft tissue reconstruction, as well as our pipeline activities related to our two important devices, the ease of use device, which was just approved by the FDA, and we think that's gonna make a big difference in the marketplace over the middle to long run. The fully automated device that Mike mentioned earlier. Both of those provide real advantages in the marketplace as well as they help us significantly with our intellectual property. You know, we very carefully scrutinize these operating expenditures, these investments. In fact, there is a very strong return on investment anticipated for each one of these pipeline activities. As a result of that, whereas we've provided revenue guidance for 20% growth this year, we have not provided actual dollar guidance for years later, but I can say that our revenue growth rates are anticipated to increase very significantly, if not dramatically, in years 2023 and beyond as soft tissue reconstruction and vitiligo indications are commercialized. It's the underlying revenue as well as the growth rates that really drive share price. You know, we think that we're significantly undervalued today, and we're continuing to hit a number of milestones in the face of macro conditions that are depressing the stock market and our sector in particular. We think for those who are patient, really good things are going to come relative to our share price down the road. Thanks, Michael. That kind of dovetails into another prevalent question asked in a number of different ways. Basically, the question is, you know, what's driving your share price? Obviously, the share price has declined. Can you provide any more color as to what's going on with the share price and what could influence it in the future? Sure. You know, we're disappointed with the share price as well. We believe that we're undervalued and that we're a very good buy opportunity right now. If you look at the analyst reports, they go along with that. I do not believe that it's execution on the side of the company. We have hit all of our milestones that we have laid out going forward despite COVID. You know, you see them on this slide here that is projected. We continue to work through the nursing shortage and everything else. I really think it's going to take the continued heads down on the business work to increase sales as we can in the burn sector, which is the smallest indication that we have. As Michael said, moving forward, for those of you who are shareholders that are patient, that there's going to be a nice hockey stick as we launch into soft tissue and vitiligo indications at the second half of next calendar year. You know, there have been hedge funds in the U.S. that have been selling, which have contributed to the depressed share price. You know, largely, what you're seeing here was a real hit due to COVID in the first quarter or the end of the first quarter in 2020. You can see if you follow the stock chart, every time we had good news and the stock goes up, you know, a number of percentage points, it goes back down, and then it goes back even further down. Now the entire sector, growth stocks in general are basically being put to the side. Not a whole lot of investor interest, at least in the United States. You know, that will come back. Right now it's really the focus is, you know, during COVID, the focus was on healthcare, especially those companies that were making vaccines or other elements of the supply chain relative to treating COVID. Now it's really, you know, backed off and it will come back. That's all the insight that I have. Michael, anything that you would add to that relative to, you know, what's driving the share price and where we are right now? Yeah. I would sort of echo many of the same things. I think macro conditions relative to inflation, the U.S. Federal Reserve announcements of increasing rates going forward to address the inflation has driven a lot of institutional investors to safer grounds, caused rebalancing of their portfolios. And at least at this point in our company lifecycle, we just simply don't have enough trading volume in the stock to soak up, if you will, that extra demand from the institutional investors to a certain degree, rotating out. Those sort of things will stabilize. As we sit here today, almost incredibly, our net valuation is about AUD 150 million Australian dollars when you back out our cash position. That's only a little more than 3x our revenue multiple. When you look at our very likely de-risk, we believe growth rates in the future, that's gonna prove to be a bargain in our view. We think that things will settle out over the next quarter. Things are off to a good start revenue-wise here in the first quarter. We feel very positive about the future. Back to questions. There seems to be a little bit of confusion in the investor community relative to what regulatory approvals AVITA has in non-U.S. markets, namely in Europe and in Australia. There appears to be a missed opportunity for revenue generation in those markets. Can you talk more about what regulatory approvals you actually have in those markets and what your future plans are to address those markets, and why not put more emphasis on them today? A great question. When we look at specifically Europe and Australia, where we do have a CE mark for Europe, we're maintaining that approval, and we do have TGA approval broadly for Australia. However, when one looks at the burn rates and what would be required to actually secure reimbursement in these markets for burns alone, it's actually a negative ROI. However, new indications, soft tissue and vitiligo, we are consistently assessing the opportunity to come back into Europe, come back into Australia. The value proposition, the ROI quickly turns positive when we have those data that we can bring back to these markets. At that time, you know, upon board approval, of course, the plan is to relaunch in Australia and in Europe when the ROI is going to be positive and it's going to make sense to go forward from a business perspective. That's gonna be a positive return on investment for the company. Yeah. That's, you know, again, relative to the regulatory approvals that we have, they're very broad. You know, the TGA approval that we have would include soft tissue wounds and vitiligo, for example, as does Europe. You know, it's just a question of getting the reimbursement and Europe going country by country and establishing the reimbursement price and then deploying a sales force there. You know, we are definitely going to be back. It's just a question of when. So there have been a number of questions that have come in the Q&A box here, and unfortunately, we're not gonna have sufficient time to address more than a couple more questions. Just to let you know, we will try to get back to you with answers quickly after the call. But in terms of one or two more questions, now that COVID is abating, does AVITA plan on intensifying its investor relations activities in Australia? Can we expect to see Mike and perhaps the team over more often than in recent years? That's a resounding yes to that question. I'm currently in Melbourne, and I will be traveling with key members of the team, the leadership team. You know, we've got some time to make up for. We haven't been able to travel from the U.S. to Australia for the better part of two years. We're very much looking forward to re-engaging on the story, showing what a really bright future the company has in spite of where the share price is today. Actually, it's a good time to get in. Insofar as travel and presence in Australia, we actually are enhancing our investor relations. We're going to be expanding our program, and you can expect to see me and Michael and others of our team present on a semi-regular basis. Thank you. With that, I'll just remind the viewers that if you would like to review this presentation in the Q&A or if you didn't, you know, you didn't hear all of it, we are going to post this on our website shortly after the call, so it will be there for your review. With that, I'll just turn it back over to Mike for any closing remarks. Well, I wanna thank everybody for their questions, as well as your attention through the presentation. I hope that you too are really seeing the value in this business. It's truly a platform technology that's making a difference in patients' lives. While it's taking a little while longer for adoption in burns, as our new indications come on board, I'm very much looking forward to sharing the story and showing a hockey stick increase. Again, can't promise anything. There's macro conditions, you know, war in the Ukraine, et cetera. Fundamentals of the business have not changed. As a matter of fact, they're better than ever. With that, again, I thank you for your kind attention, and we'll look forward to seeing you on future travels. Thank you. A special thanks to Monsoon Communications for ably hosting this event. Thank you.